13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ANAM-17-21

    Acronym: 

    ANAM-17-21

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III Tumour Stream NSCLC with weight loss
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream NSCLC with weight loss
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase III, randomised, double-blind, placebo-controlled, mutli-centre study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC.

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary Central Districts Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Not Yet Recruiting